Comparative Pharmacology
Head-to-head clinical analysis: NORGESTREL AND ETHINYL ESTRADIOL versus OGEN 625.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORGESTREL AND ETHINYL ESTRADIOL versus OGEN 625.
NORGESTREL AND ETHINYL ESTRADIOL vs OGEN .625
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norgestrel is a progestogen that suppresses gonadotropin secretion, primarily LH, inhibiting ovulation and altering cervical mucus to impede sperm penetration. Ethinyl estradiol is an estrogen that stabilizes the endometrium and provides negative feedback on gonadotropin release, contributing to contraceptive efficacy.
Estrogen replacement therapy; estrogen binds to estrogen receptors, which then translocate to the nucleus and modulate gene transcription, leading to effects such as proliferation of the endometrium and regulation of gonadotropin secretion.
One tablet (0.3 mg norgestrel/0.03 mg ethinyl estradiol) orally once daily, taken at the same time each day.
0.625 mg orally once daily
None Documented
None Documented
Norgestrel: terminal half-life ~45 hours (range 24–50 h), supporting once-daily dosing; Ethinyl estradiol: terminal half-life ~17 hours (range 10–24 h).
Estrone: 10-24 hours; equilin: 12-18 hours; terminal half-life supports once-daily dosing.
Norgestrel: 45% renal, 32% fecal as metabolites; Ethinyl estradiol: 40% renal, 60% fecal as glucuronide and sulfate conjugates.
Renal (primarily as glucuronide and sulfate conjugates, ~50-80% of a dose), fecal (~10-20%), with enterohepatic recirculation.
Category D/X
Category C
Estrogen
Estrogen